このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

韓国の前立腺がん男性におけるダロルタミドの安全性についてさらに学ぶための観察研究

2026年10月18日 更新者:Bayer

韓国人患者におけるダロルタミドの承認使用に関する市販後調査研究

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.

This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.

To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.

Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.

調査の概要

研究の種類

観察的

入学 (推定)

600

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Multiple Locations、韓国
        • 募集
        • Many locations

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

サンプリング方法

非確率サンプル

調査対象母集団

Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.

説明

Inclusion Criteria:

  • Male aged ≥19 years

  • Patients with high risk nmCPRC

    • Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
    • PSA doubling time < 10 months
  • Patients with mHSPC

    • histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
    • be candidates for androgen-deprivation therapy with/without docetaxel.
  • Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice

  • Written informed consent from subject or legal representative; assent from subject when appropriate

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice
  • Participants with contraindication according to the locally approved prescribing information

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Male patients with nmCRPC or mHSPC

Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number, severity of adverse events (including SAEs)
時間枠:From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Number, severity of adverse drug reactions (including SADRs)
時間枠:From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse events
時間枠:From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse drug reactions
時間枠:From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

二次結果の測定

結果測定
メジャーの説明
時間枠
ダロルタミドを終了する理由
時間枠:最長52週間
最長52週間
ダロルタミドの用量および用量変更
時間枠:最長52週間
最長52週間
Metastasis-free survival (MFS) by nmCRPC indication
時間枠:Up to 52 weeks

MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
時間枠:Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
時間枠:Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by nmCRPC indication
時間枠:Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
時間枠:Up to 52 weeks

Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
時間枠:Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
時間枠:Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by mHSPC indication
時間枠:Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
時間枠:Up to 52 weeks

Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide.

Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
時間枠:Up to 52 weeks

Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.

Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
時間枠:Up to 52 weeks

Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first.

Up to 52 weeks
Duration of Darolutamide treatment
時間枠:Up to 52 weeks

Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death).

Up to 52 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年9月25日

一次修了 (推定)

2028年3月31日

研究の完了 (推定)

2028年6月30日

試験登録日

最初に提出

2024年3月21日

QC基準を満たした最初の提出物

2024年3月21日

最初の投稿 (実際)

2024年3月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月20日

QC基準を満たした最後の更新が送信されました

2026年10月18日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 20654

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する